{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T16:28:02Z","timestamp":1781108882122,"version":"3.54.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,19]]},"DOI":"10.7759\/cureus.82571","type":"journal-article","created":{"date-parts":[[2025,4,19]],"date-time":"2025-04-19T11:44:06Z","timestamp":1745063046000},"source":"Crossref","is-referenced-by-count":2,"title":["Analysis of Ubiquitin-Conjugating Enzyme E2T (UBE2T) Protein Levels in the Bone Marrow Biopsy Specimens of Patients With Multiple Myeloma"],"prefix":"10.7759","author":[{"given":"Fei","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00165-X","article-title":"The epidemiological landscape of multiple myeloma: a global cancer registry estimate of disease burden, risk factors, and temporal trends","volume":"9","author":"Huang J","year":"2022","unstructured":"Huang J, Chan SC, Lok V, et al.. The epidemiological landscape of multiple myeloma: a global cancer registry estimate of disease burden, risk factors, and temporal trends. Lancet Haematol. 2022, 9:670-7. 10.1016\/S2352-3026(22)00165-X","journal-title":"Lancet Haematol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-050522-033815","article-title":"New biological therapies for multiple myeloma","volume":"75","author":"Garfall AL","year":"2024","unstructured":"Garfall AL. New biological therapies for multiple myeloma. Annu Rev Med. 2024, 75:13-29. 10.1146\/annurev-med-050522-033815","journal-title":"Annu Rev Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.74970","article-title":"Advancements in the treatment of multiple myeloma","volume":"16","author":"Zavaleta-Monestel E","year":"2024","unstructured":"Zavaleta-Monestel E, Quesada-Villase\u00f1or R, Barrantes-L\u00f3pez M, et al.. Advancements in the treatment of multiple myeloma. Cureus. 2024, 16:e74970. 10.7759\/cureus.74970","journal-title":"Cureus"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27327","article-title":"High-risk multiple myeloma: redefining genetic, clinical, and functional high-risk disease in the era of molecular medicine and immunotherapy","volume":"99","author":"Rees MJ","year":"2024","unstructured":"Rees MJ, Kumar S. High-risk multiple myeloma: redefining genetic, clinical, and functional high-risk disease in the era of molecular medicine and immunotherapy. Am J Hematol. 2024, 99:1560-75. 10.1002\/ajh.27327","journal-title":"Am J Hematol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcdb.2023.08.002","article-title":"Proteotoxic stress and the ubiquitin proteasome system","volume":"156","author":"Kandel R","year":"2024","unstructured":"Kandel R, Jung J, Neal S. Proteotoxic stress and the ubiquitin proteasome system. Semin Cell Dev Biol. 2024, 156:107-20. 10.1016\/j.semcdb.2023.08.002","journal-title":"Semin Cell Dev Biol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.247015","article-title":"Multiple myeloma: the (r)evolution of current therapy and a glance into future","volume":"105","author":"Gulla A","year":"2020","unstructured":"Gulla A, Anderson KC. Multiple myeloma: the (r)evolution of current therapy and a glance into future. Haematologica. 2020, 105:2358-67. 10.3324\/haematol.2020.247015","journal-title":"Haematologica"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1039\/d2cs00116k","article-title":"Discovery of CRBN as a target of thalidomide: a breakthrough for progress in the development of protein degraders","volume":"51","author":"Yamamoto J","year":"2022","unstructured":"Yamamoto J, Ito T, Yamaguchi Y, Handa H. Discovery of CRBN as a target of thalidomide: a breakthrough for progress in the development of protein degraders. Chem Soc Rev. 2022, 51:6234-50. 10.1039\/d2cs00116k","journal-title":"Chem Soc Rev"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2024.123125","article-title":"Bortezomib in cancer therapy: Mechanisms, side effects, and future proteasome inhibitors","volume":"358","author":"Sogbein O","year":"2024","unstructured":"Sogbein O, Paul P, Umar M, Chaari A, Batuman V, Upadhyay R. Bortezomib in cancer therapy: Mechanisms, side effects, and future proteasome inhibitors. Life Sci. 2024, 358:123125. 10.1016\/j.lfs.2024.123125","journal-title":"Life Sci"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1186\/s12920-024-01937-0","article-title":"The prognostic significance of ubiquitination-related genes in multiple myeloma by bioinformatics analysis","volume":"17","author":"Zhang F","year":"2024","unstructured":"Zhang F, Chen XL, Wang HF, Guo T, Yao J, Jiang ZS, Pei Q. The prognostic significance of ubiquitination-related genes in multiple myeloma by bioinformatics analysis. BMC Med Genomics. 2024, 17:164. 10.1186\/s12920-024-01937-0","journal-title":"BMC Med Genomics"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/s41417-018-0070-x","article-title":"High expression of UBE2T predicts poor prognosis and survival in multiple myeloma","volume":"26","author":"Zhang W","year":"2019","unstructured":"Zhang W, Zhang Y, Yang Z, et al.. High expression of UBE2T predicts poor prognosis and survival in multiple myeloma. Cancer Gene Ther. 2019, 26:347-55. 10.1038\/s41417-018-0070-x","journal-title":"Cancer Gene Ther"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2018.0002","article-title":"NCCN guidelines insights: multiple myeloma, version 3.2018","volume":"16","author":"Kumar SK","year":"2018","unstructured":"Kumar SK, Callander NS, Alsina M, et al.. NCCN guidelines insights: multiple myeloma, version 3.2018. J Natl Compr Canc Netw. 2018, 16:11-20. 10.6004\/jnccn.2018.0002","journal-title":"J Natl Compr Canc Netw"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar SV","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, et al.. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014, 15:538-48. 10.1016\/S1470-2045(14)70442-5","journal-title":"Lancet Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised International Staging System for multiple myeloma: a report from International Myeloma Working Group","volume":"33","author":"Palumbo A","year":"2015","unstructured":"Palumbo A, Avet-Loiseau H, Oliva S, et al.. Revised International Staging System for multiple myeloma: a report from International Myeloma Working Group. J Clin Oncol. 2015, 33:2863-9. 10.1200\/JCO.2015.61.2267","journal-title":"J Clin Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1089\/dna.2020.5823","article-title":"Increased expression of UBE2T predicting poor survival of epithelial ovarian cancer: based on comprehensive analysis of UBE2s, clinical samples, and the GEO database","volume":"40","author":"Zou R","year":"2021","unstructured":"Zou R, Xu H, Li F, Wang S, Zhu L. Increased expression of UBE2T predicting poor survival of epithelial ovarian cancer: based on comprehensive analysis of UBE2s, clinical samples, and the GEO database. DNA Cell Biol. 2021, 40:36-60. 10.1089\/dna.2020.5823","journal-title":"DNA Cell Biol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.111160","article-title":"Affinity-based protein profiling to reveal targets of puerarin involved in its protective effect on cardiomyocytes","volume":"134","author":"Huang S","year":"2021","unstructured":"Huang S, Wang FJ, Lin H, Liu T, Zhao CX, Chen LG. Affinity-based protein profiling to reveal targets of puerarin involved in its protective effect on cardiomyocytes. Biomed Pharmacother. 2021, 134:111160. 10.1016\/j.biopha.2020.111160","journal-title":"Biomed Pharmacother"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000181","article-title":"Amplification and overexpression of E2 ubiquitin conjugase UBE2T promotes homologous recombination in multiple myeloma","volume":"3","author":"Alagpulinsa DA","year":"2019","unstructured":"Alagpulinsa DA, Kumar S, Talluri S, et al.. Amplification and overexpression of E2 ubiquitin conjugase UBE2T promotes homologous recombination in multiple myeloma. Blood Adv. 2019, 3:3968-72. 10.1182\/bloodadvances.2019000181","journal-title":"Blood Adv"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-024-00774-8","article-title":"Fanconi anaemia pathway induces chromosome shattering","volume":"24","author":"Brewer G","year":"2024","unstructured":"Brewer G. Fanconi anaemia pathway induces chromosome shattering. Nat Rev Cancer. 2024, 24:827. 10.1038\/s41568-024-00774-8","journal-title":"Nat Rev Cancer"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2024.08.001","article-title":"The Fanconi anemia pathway induces chromothripsis and ecDNA-driven cancer drug resistance","volume":"187","author":"Engel JL","year":"2024","unstructured":"Engel JL, Zhang X, Wu M, et al.. The Fanconi anemia pathway induces chromothripsis and ecDNA-driven cancer drug resistance. Cell. 2024, 187:P6055-70.E22. 10.1016\/j.cell.2024.08.001","journal-title":"Cell"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-022-01292-9","article-title":"Fanconi anemia-associated signature in cancer","volume":"55","author":"Danovi S","year":"2023","unstructured":"Danovi S. Fanconi anemia-associated signature in cancer. Nat Genet. 2023, 55:1. 10.1038\/s41588-022-01292-9","journal-title":"Nat Genet"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024025541","article-title":"Fanconi anemia: realizing hematopoietic cure","volume":"144","author":"Satty AM","year":"2024","unstructured":"Satty AM. Fanconi anemia: realizing hematopoietic cure. Blood. 2024, 144:1245-6. 10.1182\/blood.2024025541","journal-title":"Blood"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-05253-4","article-title":"Genomic signature of Fanconi anaemia DNA repair pathway deficiency in cancer","volume":"612","author":"Webster AL","year":"2022","unstructured":"Webster AL, Sanders MA, Patel K, et al.. Genomic signature of Fanconi anaemia DNA repair pathway deficiency in cancer. Nature. 2022, 612:495-502. 10.1038\/s41586-022-05253-4","journal-title":"Nature"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-51090-6","article-title":"The Fanconi anemia core complex promotes CtIP-dependent end resection to drive homologous recombination at DNA double-strand breaks","volume":"15","author":"van de Kooij B","year":"2024","unstructured":"van de Kooij B, van der Wal FJ, Rother MB, et al.. The Fanconi anemia core complex promotes CtIP-dependent end resection to drive homologous recombination at DNA double-strand breaks. Nat Commun. 2024, 15:7076. 10.1038\/s41467-024-51090-6","journal-title":"Nat Commun"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2006.06.024","article-title":"UBE2T is the E2 in the Fanconi anemia pathway and undergoes negative autoregulation","volume":"23","author":"Machida YJ","year":"2006","unstructured":"Machida YJ, Machida Y, Chen Y, Gurtan AM, Kupfer GM, D'Andrea AD, Dutta A. UBE2T is the E2 in the Fanconi anemia pathway and undergoes negative autoregulation. Mol Cell. 2006, 23:589-96. 10.1016\/j.molcel.2006.06.024","journal-title":"Mol Cell"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2023.02.025","article-title":"Targeting UBE2T potentiates gemcitabine efficacy in pancreatic\u00a0cancer by regulating pyrimidine metabolism and replication stress","volume":"164","author":"Jiang X","year":"2023","unstructured":"Jiang X, Ma Y, Wang T, et al.. Targeting UBE2T potentiates gemcitabine efficacy in pancreatic\u00a0cancer by regulating pyrimidine metabolism and replication stress. Gastroenterology. 2023, 164:1232-47. 10.1053\/j.gastro.2023.02.025","journal-title":"Gastroenterology"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-020-01734-4","article-title":"UBE2T-regulated H2AX monoubiquitination induces hepatocellular carcinoma radioresistance by facilitating CHK1 activation","volume":"39","author":"Sun J","year":"2020","unstructured":"Sun J, Zhu Z, Li W, et al.. UBE2T-regulated H2AX monoubiquitination induces hepatocellular carcinoma radioresistance by facilitating CHK1 activation. J Exp Clin Cancer Res. 2020, 39:222. 10.1186\/s13046-020-01734-4","journal-title":"J Exp Clin Cancer Res"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-04596-0","article-title":"UBE2T-mediated Akt ubiquitination and Akt\/\u03b2-catenin activation promotes hepatocellular carcinoma development by increasing pyrimidine metabolism","volume":"13","author":"Zhu Z","year":"2022","unstructured":"Zhu Z, Cao C, Zhang D, Zhang Z, Liu L, Wu D, Sun J. UBE2T-mediated Akt ubiquitination and Akt\/\u03b2-catenin activation promotes hepatocellular carcinoma development by increasing pyrimidine metabolism. Cell Death Dis. 2022, 13:154. 10.1038\/s41419-022-04596-0","journal-title":"Cell Death Dis"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-020-01572-w","article-title":"A novel UBE2T inhibitor suppresses Wnt\/\u03b2-catenin signaling hyperactivation and gastric cancer progression by blocking RACK1 ubiquitination","volume":"40","author":"Yu Z","year":"2021","unstructured":"Yu Z, Jiang X, Qin L, et al.. A novel UBE2T inhibitor suppresses Wnt\/\u03b2-catenin signaling hyperactivation and gastric cancer progression by blocking RACK1 ubiquitination. Oncogene. 2021, 40:1027-42. 10.1038\/s41388-020-01572-w","journal-title":"Oncogene"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S405450","article-title":"UBE2T promotes temozolomide resistance of glioblastoma through regulating the wnt\/\u03b2-catenin signaling pathway","volume":"17","author":"Wang Y","year":"2023","unstructured":"Wang Y, Gao G, Wei X, Zhang Y, Yu J. UBE2T promotes temozolomide resistance of glioblastoma through regulating the wnt\/\u03b2-catenin signaling pathway. Drug Des Devel Ther. 2023, 17:1357-69. 10.2147\/DDDT.S405450","journal-title":"Drug Des Devel Ther"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010782","article-title":"UBE2T\/CDC42\/CD276 signaling axis mediates brain metastasis of triple-negative breast cancer via lysosomal autophagy","volume":"13","author":"Shi LL","year":"2025","unstructured":"Shi LL, Chen Y, Xie MX, et al.. UBE2T\/CDC42\/CD276 signaling axis mediates brain metastasis of triple-negative breast cancer via lysosomal autophagy. J Immunother Cancer. 2025, 13:e010782. 10.1136\/jitc-2024-010782","journal-title":"J Immunother Cancer"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.217409","article-title":"Targeting UBE2T suppresses breast cancer stemness through CBX6-mediated transcriptional repression of SOX2 and NANOG","volume":"611","author":"Wang K","year":"2024","unstructured":"Wang K, He Q, Jiang X, et al.. Targeting UBE2T suppresses breast cancer stemness through CBX6-mediated transcriptional repression of SOX2 and NANOG. Cancer Lett. 2024, 611:217409. 10.1016\/j.canlet.2024.217409","journal-title":"Cancer Lett"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/357360-analysis-of-ubiquitin-conjugating-enzyme-e2t-ube2t-protein-levels-in-the-bone-marrow-biopsy-specimens-of-patients-with-multiple-myeloma","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,19]],"date-time":"2025-04-19T11:44:07Z","timestamp":1745063047000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/357360-analysis-of-ubiquitin-conjugating-enzyme-e2t-ube2t-protein-levels-in-the-bone-marrow-biopsy-specimens-of-patients-with-multiple-myeloma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,19]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.82571","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4,19]]}}}